Enfusion, INC Form 4 insider transactions

ICONIQ Strategic Partners V, L.P. and related entities report the disposition of Enfusion, Inc. shares and common units following the merger with Clearwater Analytics Holdings, Inc.

Director Roy Luo reports the disposal of Enfusion shares and common units following the merger agreement with Clearwater Analytics, where eligible shares were converted into the right to receive cash or Clearwater Analytics stock.

Neal Pawar, Chief Operating Officer of Enfusion, Inc., reports the disposal of shares following the company's merger with Clearwater Analytics Holdings, Inc.

Bradley Herring, CFO of Enfusion, Inc., reports the disposal of all Enfusion securities following the completion of a merger with Clearwater Analytics Holdings, Inc.

Oleg Movchan, CEO of Enfusion, Inc., reports the disposal of shares following the merger with Clearwater Analytics Holdings, Inc.

Lawrence Leibowitz, a director at Enfusion, Inc., reports the disposal of all Enfusion shares following the completion of a merger with Clearwater Analytics Holdings, Inc.

Director Jan Hauser reports the disposal of Enfusion shares following the completion of a merger with Clearwater Analytics, marking an exit filing.

Valeria Gutowski, Chief Accounting Officer of Enfusion, Inc., reports the disposal of all Enfusion securities following the completion of a merger with Clearwater Analytics Holdings, Inc.

Matthew Campobasso, General Counsel of Enfusion, Inc., reports the disposal of shares following the company's merger with Clearwater Analytics Holdings, Inc.

Deirdre Somers, a director of Enfusion, Inc., reported the disposal of 41,675 shares of Class A Common Stock following the company's merger with Clearwater Analytics Holdings, Inc.

Kathleen DeRose, a director at Enfusion, Inc., reported the disposal of 60,716 shares of Class A Common Stock following the company's merger with Clearwater Analytics Holdings, Inc.

Director Michael Spellacy reports the disposal of Enfusion shares following the completion of a merger with Clearwater Analytics, marking his exit filing.

Bronwen Bastone, Chief People Officer of Enfusion, Inc., reports the disposal of shares and stock options following the merger agreement with Clearwater Analytics Holdings, Inc.

Bradford E. Bernstein, a director and 10% owner of Enfusion, Inc., reported the disposal of 32,440,463 shares of Class A Common Stock due to the merger with Clearwater Analytics Holdings, Inc.

Clearwater Analytics and Enfusion have announced the preliminary results of the election by Enfusion shareholders regarding the form of merger consideration they wish to receive in connection with Clearwater's acquisition of Enfusion.

Clearwater Analytics and Enfusion have announced the preliminary results of the election by Enfusion shareholders regarding the form of merger consideration they wish to receive in connection with Clearwater's acquisition of Enfusion.

Enfusion releases supplemental disclosures related to its pending acquisition by Clearwater Analytics, addressing stockholder lawsuits and updating financial projections.

Clearwater Analytics and Enfusion have set April 16, 2025, as the deadline for Enfusion shareholders to elect the form of merger consideration they wish to receive in connection with Clearwater's acquisition of Enfusion.

Enfusion and Clearwater Analytics announced the deadline for Enfusion shareholders to elect their preferred form of merger consideration is April 16, with the transaction expected to close around April 21, pending shareholder approval and customary conditions.

Clearwater Analytics and Enfusion provide an update to the joint election procedure for Enfusion stockholders regarding the merger consideration.

Bronwen Bastone, Chief People Officer of Enfusion, Inc., sold 3,126 shares of Class A Common Stock on March 5, 2025, to cover tax withholding obligations.

Matthew Campobasso, General Counsel of Enfusion, Inc., sold 1,695 shares of Class A Common Stock on March 5, 2025, to cover tax withholding obligations.

Enfusion's CEO, Oleg Movchan, sold 11,452 shares of Class A Common Stock to cover tax withholding obligations related to share issuance.

Enfusion's Chief Operating Officer, Neal Pawar, sold 14,560 shares of Class A Common Stock on March 5, 2025, to cover tax withholding obligations related to share issuance.

Valeria Gutowski, Chief Accounting Officer of Enfusion, Inc., sold 542 shares of Class A Common Stock on March 5, 2025, to cover tax withholding obligations.

Enfusion's Chief Financial Officer, Bradley Herring, sold 4,645 shares of Class A Common Stock on March 5, 2025, to cover tax withholding obligations.

Valeria Gutowski, Chief Accounting Officer of Enfusion, Inc., reports the sale of 1,233 shares of Class A Common Stock to cover tax withholding obligations.

Valeria Gutowski, Chief Accounting Officer of Enfusion, Inc., sold 219 shares of Class A Common Stock on March 3, 2025, to cover tax withholding obligations.

Enfusion's Chief Operating Officer, Neal Pawar, sold 2,769 shares of Class A Common Stock on March 3, 2025, to cover tax withholding obligations.

Oleg Movchan, CEO of Enfusion, Inc., sold shares of Class A Common Stock to cover tax withholding obligations related to the issuance of shares.